Related Experiment Video
Updated: May 24, 2026
13:18
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
On pharmacogenomics in pharmacy benefit management
J Russell Teagarden1, Eric J Stanek
1Scientific Affairs, Advanced Clinical Science and Research, Medco Health Solutions, Inc., 100 Parsons Pond Drive, Franklin Lakes, NJ 07417, USA. russell_teagarden@medco.com
Pharmacotherapy
|March 7, 2012
Summary
Pharmacy benefit management and pharmacogenomics are merging, offering precise healthcare coverage. This integration enhances clinical programs and navigates legal considerations for future opportunities.
Area of Science:
- Pharmacogenomics and Pharmacy Benefit Management
Background:
- Pharmacogenomic tests are increasingly accessible and affordable for clinical use.
- Pharmacy benefit payers are seeking precise applications for coverage policies and clinical programs.
Purpose of the Study:
- To describe the integration of pharmacogenomics into pharmacy benefit management.
- To detail the application of pharmacogenomics in benefit coverage and clinical programs.
- To discuss legal, ethical, and future aspects of pharmacogenomics in pharmacy benefits.
Main Methods:
- Review of current trends and applications of pharmacogenomics in pharmacy benefits.
- Discussion of clinical program development and implementation.
- Analysis of legal and ethical dimensions, including genetic exceptionalism.
Main Results:
- Pharmacogenomics offers a precise approach for pharmacy benefit management.
- Integration into coverage policies and clinical programs is feasible and beneficial.
- Ongoing research and defined roles for payers are crucial for development.
Conclusions:
- The convergence of pharmacogenomics and pharmacy benefit management presents significant opportunities.
- Navigating legal and ethical considerations is essential for successful implementation.
- Future development requires continued research and collaboration among stakeholders.
Related Concept Videos
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...